175 search results for: type 2 inflammation

Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
Dermatology
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
expert video

Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.

View more
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Dermatology
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Podcast

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

View more
What role does IL-4 and IL-13 have in driving <b>Type</b> <b>2</b> inflammatory skin disease (AD, PN, CSU)?
Dermatology
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
expert video

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

View more
ERS <b>2</b>0<b>2</b>5 | <b>Type</b> <b>2</b> Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes
Pulmonology
ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes
videoanimation

Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

View more
Impact of Advanced Systemic Therapies on Disease Control in AD
Dermatology
Impact of Advanced Systemic Therapies on Disease Control in AD
expert video

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

View more
ADVENT in Orlando, FL 2025
Congress
7
March
2025
Congress
ADVENT in Orlando, 2025

Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.

TBD
Dermatology
Prurigo Nodularis (PN): Understanding Its Clinical Features, Complex Burden, and Underlying Mechanisms
Infographic

Explore the clinical features, complex burden, and underlying mechanisms of PN.

View more
COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
COPD and Asthma: What's the Difference and Is There a Link?
interactivity

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

View more
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
Pulmonology
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
videoanimation

Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

View more
Current systemic therapies have been shown to induce remission in a subset of AD patients
Dermatology
Current systemic therapies have been shown to induce remission in a subset of AD patients
expert video

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

View more
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dermatology
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
expert video

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

View more
ERS <b>2</b>0<b>2</b>4 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Pulmonology
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
expert video

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.

View more